Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosaprepitant vs Aprepitant for CINV in Gynecological Cancer
NCT01432015Phase 4Completed
- Sponsor
- Gynecologic Oncology Associates
- Start
- Sep 2011
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fosaprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Gynecologic Oncology Associates. Primary endpoint: Overall Complete Response Rate at 13 months. Started Sep 2011; status: completed.
02
Drugs
fosaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01432015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01432015.